Q-omics provides the consensus-scored BUD13P1 profile across patient tissues and cancer cell-line models. BUD13P1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, BUD13P1 is differentially expressed in 10, with the highest sampling consensus in UCEC. Additionally, BUD13P1 RNA expression shows 16,842 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, UCEC, and UVM as cancer lineages where BUD13P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BUD13P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BUD13P1 survival associations across molecular data types. BUD13P1 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BUD13P1 RNA expression–survival associations across cancer types. High BUD13P1 expression shows unfavorable associations in BLCA, PAAD, LGG, UVM and UCEC, but favorable associations in LUAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for BUD13P1 RNA expression.
This table summarizes BUD13P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for BUD13P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BUD13P1 shows lower tumor expression in UCEC, BRCA and COAD and higher tumor expression in THCA, PRAD and LUSC. The UCEC box plot shows higher BUD13P1 RNA expression in normal versus tumor tissue (log2 FC = −0.176, t-test p = .004).
This table shows molecular features associated with BUD13P1 in patient tissues and cancer cell lines. In patient samples, BUD13P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
